Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Quantitative measures of the ventricular fibrillation waveform at the outset of resuscitation are associated with survival. However, little is known about the course of these measures during resuscitation and how this course is related to outcome.
Objective: The purpose of this study was to determine how waveform measures change over the course of resuscitation and whether these changes might be used to guide resuscitation.
Methods: We evaluated 390 persons treated by emergency providers following out-of-hospital ventricular fibrillation arrest. We assessed the ventricular fibrillation waveform using the amplitude spectrum area (AMSA) from the defibrillator's continuous electrocardiogram measured before each of the first three shocks. We used logistic regression to evaluate the relationship of AMSA and the change in AMSA with favorable neurologic survival as determined by the Cerebral Performance Category at hospital discharge 1-2.
Results: Of the 390 patients who received an initial shock, 273 required a second shock and 210 required a third shock. The mean (standard deviation) for AMSA was 9.64 (0.52) for the 873 total shock cycles. AMSA₁ measured before the first shock was strongly associated with favorable neurologic survival (odds ratio [OR] 3.40, 95% confidence interval [CI] [2.48, 4.66] for 1 SD change). We observed a similar relationship for second-shock AMSA₂ (OR 3.53, 95% CI [2.42, 5.14]) and third-shock AMSA₃ (OR 3.10, 95% CI [2.03, 4.73]). The median change in AMSA was 0.24 for ΔAMSA₁₋₂ and 0.21 for ΔAMSA₂₋₃. A positive median change in AMSA between shocks was associated with favorable neurologic survival (OR 1.44, 95% CI [1.16, 1.80] for ΔAMSA₁₋₂ and OR 1.31, 95% CI [1.01, 1.71] for ΔAMSA₂₋₃).
Conclusion: Given their prognostic and dynamic qualities, quantitative waveform measures may provide an effective real-time strategy to guide individual treatment and improve survival.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hrthm.2013.10.049 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Beyond Tachycardia-Induced Cardiomyopathy: ABCC9-Related Dilated Cardiomyopathy and Familial Atrial Fibrillation.
JACC Case Rep
September 2025
Division of Academic Affairs and Research, Orlando Regional Medical Center, Orlando, Florida, USA. Electronic address:
Background: Tachycardia-induced cardiomyopathy (TICM) is typically reversible with rhythm control, but individual susceptibility remains poorly understood and may reflect genetic predisposition.
Case Summary: A 66-year-old woman with paroxysmal atrial fibrillation (AF) presented with new-onset heart failure. Genetic testing identified a likely pathogenic heterozygous ABCC9 gene variant (c.
Atrial Functional Mitral Regurgitation and Exercise-Induced Changes in Heart Failure With Preserved Ejection Fraction.
JACC Cardiovasc Imaging
September 2025
Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium; Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium. Electronic address:
Background: Atrial functional mitral regurgitation (AFMR) is prevalent among patients with heart failure with preserved ejection fraction (HFpEF) and associated with adverse outcome, yet this bidirectional association remains underexplored.
Objectives: The purpose of this study was to elucidate the pathophysiological and prognostic significance of AFMR in HFpEF, both at rest and during exercise.
Methods: In this multicenter cohort study, consecutive patients with HFpEF underwent cardiopulmonary exercise testing with echocardiography, with a particular focus on mitral regurgitation (MR) severity assessment in rest and during exercise.
Prognostic value of preoperative NT-proBNP in patients with obstructive hypertrophic cardiomyopathy undergoing septal myectomy.
JTCVS Open
August 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minn.
Background: Proper risk stratification tools for patients with obstructive hypertrophic cardiomyopathy (oHCM) undergoing septal myectomy are lacking. Our objective was to assess the predictive value of preoperative N-terminal pro-brain natriuretic peptide (NT-proBNP) on perioperative outcomes and late survival in patients with oHCM undergoing transaortic septal myectomy.
Methods: Between 2008 and 2021, 834 patients with preoperative NT-proBNP measurements underwent septal myectomy.
From crisis to recovery: A case report on nursing strategies for hepatitis E post-cardiac arrest.
Medicine (Baltimore)
September 2025
Nutrition Department, Hangzhou Third People's Hospital, Hangzhou, Zhejiang, China.
Rationale: Extracorporeal membrane oxygenation (ECMO) is a life-support technology for refractory cardiac arrest, but the massive blood transfusions required during treatment significantly increase the risk of transfusion-related infections. Hepatitis E virus (HEV) - traditionally linked to fecal-oral transmission - is increasingly recognized as a transfusion-transmitted pathogen, especially in emergency settings where urgent blood product infusion is common and routine HEV screening in blood banks is often lacking. However, nursing strategies for managing acute HEV infection after ECMO remain poorly defined, highlighting the need to address this clinical gap.
View Article and Find Full Text PDFThe CONDUCT-AF trial: Rationale and design of a prospective, randomized, multicentre study comparing conduction system and biventricular pacing in patients undergoing atrioventricular node ablation for heart failure with atrial fibrillation.
Eur J Heart Fail
September 2025
Cardiology Department, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Aims: There is a lack of data from randomized clinical trials comparing treatment outcomes between conduction system pacing (CSP) modalities and biventricular pacing (BVP) in symptomatic patients with refractory atrial fibrillation (AF) scheduled for atrioventricular node ablation (AVNA). The CONDUCT-AF investigates whether CSP is non-inferior to BVP in improving left ventricular ejection fraction (LVEF) and clinical outcomes in heart failure (HF) patients with symptomatic AF undergoing AVNA.
Methods: This study is an investigator-initiated, prospective, randomized, multicentre clinical trial conducted across 10 European centres, enrolling 82 patients with symptomatic AF, HF with reduced LVEF, and narrow QRS.